...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Goodbye Q3, Hello Q4. RVX in the Next 2 Weeks.

While we are waiting to hear something from RVX, here is a reminder of upcoming events. Most likely RVX will update their events page with these once Q4 rolls into town. The big one in my opinion is the R&D update in 2 weeks (October 13). So even if we don't hear anything substantial in the next 2 weeks leading up to this R&D update, we will very likely get some new info/updates at the R&D update regarding one or more of the following: BETonMACE Trial, Renal Trial(s), Complement/PNH Trial, announcement/plans/timeline for 2nd molecule, and 2nd licensing deal. There is too much time (2 hours) and too many speakers (5) for it to simply be a re-hash of all old stuff. At least that's my hope!

BioNetwork Partnering Summit. October 5-7, 2016, Laguna Niguel, CA; Ken Lebioda listed as speaker

Resverlogix’s R&D Update with World-Renowned Key Opinion Leaders, October 13, 2016 12:00-2:15 EST, The Yale Club of NYC; Presentations by Kausik Ray, Kamyar Kalantar-Zadeh, Donald J. McCaffrey, Michael Sweeney, Dr. Ewelina Kulikowski.

BIO-Europe, November 7-9, 2016, Cologne, Germany; Resverlogix listed as presenting company

American Heart Association, November 12-15, 2016, New Orleans, LA; Poster presentation "Apabetalone (RVX-208) Reduces Expression of Acute Phase Response Markers in vitro and in Patients With Cardiovascular Disease"

Resverlogix AGM...........To Be Determined

Share
New Message
Please login to post a reply